We are initiating coverage of RXi Pharmaceuticals Corp (RXII) with a $20.00 price target based on our estimates for a 2023 launch of RXI-109 and a 2022 launch of Samcyprone, both through the efforts ...
On August 1st RXi Pharmaceuticals (RXII) issued a press release announcing positive results from their RXI-109-1501 Phase I/II trial for retinal scarring. The primary outcome for the trial was to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results